Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
AstraZeneca and FibroGen are joining to develop FG-4592, a FibroGen compound set to enter Phase III clinical trials as a treatment for anemia associated with chronic kidney disease and end-stage renal disease. AstraZeneca will pay San Francisco-based FibroGen $350 million plus future milestone payments of up to $465 million. FG-4592 is a small molecule that works through the body’s oxygen-sensing system to help produce red blood cells.
This article has been sent to the following recipient: